Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Very tight spread on this one which looks deciving. I bought for 27.4 but could sell straight away for 27.3. My buys registered as sells , i suspect most buys are coming up as sells because they are below mid price.

Making everyone very jittery!!

Well, I sent the email and got a very nice man answering giving some very positive feedback about the products, the latest figures regarding sales and their expectations for the future. As soon as I have permission from the author, I will post them....

Will give him a call the morra !!

Save the whale...... 'cos they're cute !

Well, just spoke to Ewan Phillips, who is the finance director at Deltex. I asked him some questions about the company and he responded very positively. These are his answers and are reproduced verbatim with his permission .

Q. If half of the major hospitals in the UK are already
>> using cardioQ, given that the results show a modest sales growth, how
>> do you foresee improving that growth in the medium term ?

A. It is now over two-thirds (i.e. 200+) of the major hospitals that have
one or more CardioQs. The vast majority of these have one or two
monitors each. There are now eleven hospitals with sufficient monitors
(typically 8 to 10, but can be more) to allow them to treat most of
their moderate & major risk surgery patients & a few more with multiple
monitors but which are mostly in critical care rather than operating
theatres. Growth comes both from monitor sales and then from recurring
revenues from more common usage of probes.

Q. >> Are each of these hospitals only using one monitor at the moment and
>> you hope to see large orders placed for the equipment after the
>> psychological barrier of using new techniques is lowered ?

A. Yes - there are many barriers, first to clinical change in theory then
to clinical change in practice, but once established, monitoring
devices tend to have a long installed life.

Q. >> Or is the growth coming from the sale of the disposable probes that
>> are also being supplied ?

A. Yes - both from monitors then probes.

Q. > I understand that you are hopeful that the adoption process will be
>> repeated throughout Europe, which will obviously increase sales
>> without the attendant expenditure that you are currently
>> experiencing. Will this be a large enough sales target to give good
>> shareholder value and prospects ?

A. There are circa one million patients a year in the UK NHS alone who
would benefit from the device (based on published trials) with similar
numbers relative to population in all other developed countries.
Market size also tend to grow as use grows.

Q. >> What life are you estimating the monitoring equipment to have before
>> a replacement unit is required ?

A. Ten years plus - not a major issue once established as the disposable
probes provide the main revenue source.

He also told me the prices of the equipment and I have to say (without quoting prices) that I was very surprised at how cash generative this will become.

Above all....... he gave me the time of day to talk for as long as I wanted, was happy to answer any of the questions and was very positive about the future. All this and he was at home on his mobile....... How many FD's will do that for you ?

I'm in for more.......

in the longer term deltex has got to be a winner and a target for some of the bigger health suppliers. it has a product that works, cuts hospital time and costs - good for the patients, the hospitals and for the politicians. all we need now is for the medical mindset to change. also on rns a few days ago there was approval for the method from another 4 european countries, opening the way for ongoing expansion

also going down the same route (but for different conditions} is LIDCO (LID) which also promises to cut time and costs with its heart monitoring gear - worth a look but DYOR.

Jimwren, where did you see the RNS about the approval from European countries ?

I am very happy that Deltex are raising another 1.25m to fund further development of the completely non-invasive probe. Another improvement to patient comfort and probably more expensive to buy. (ching ching) It seems that they will use the current one during medical procedures on the table and the new one after surgery. (I think) I also like the fact that the money is being raised through an institutional placing.

I have got one of those warm fuzzy feelings about this and assuming that the growth and acceptance of the kit continues, (even though it's only really starting) then this company is going to reap the rewards handsomely.

sorry, got my medical companies muddled - the approval comments should relate to LIDCO - see my comments above. Nonetheless Deltex still looks a good buy for all the right reasons

Crash, baby, crash, baby, crash, baby, crash!

Oh yeah! Go down, go down, go down!

What's happening to this share? Thank you to whoever is pushing the price down so I can stock up ready for the price to climb again. I have to say I am surprised at the drop. Maybe Deltex is just a bit too long term (i.e. a year or two) to really take off. Possibly also everyone is selling shares to have some spare cash to buy christmas presents.

Me, I'd rather buy myself a christmas present: a nice large chunk of DEMG. Oh, thank you! Just what I wanted! Such a surprise!

hope your right AD... holding onto a nice fat loss here!

Took the opputunity to add on today`s drop. still good long term prospects, maybe oversold on opening? DYOR

yes, imo this is a very good statement (apart from the delay in orders!) and in true nhs style. But I believe that once the first ordes are received the snowball will start rolling.
A great buying opp'. DYOR.

Glad I didn't panic and held my nerve, hope I can free to funds soon to buy again at these prices.

Minor setback I reckon..Company & products still good. it's always going to be difficult dealing with the NHS but when the sales do start coming in the SP will rocket (imho) I'm holding on :)

I have now joined in--picked up afew this morning. Great prospects but patience needed.

Hi all.

I have just go into this one. Ive been looking at it for a while & decided to jump in before it takes off. Looks like the recent drop was down to a profit warning if orders were not placed with them by 31st december 2004. They were not placed but it looks like 2005 will be good for DEMG.

Here is a recent trading statement made by the company,


Deltex Medical Group PLC
16 December 2004

Deltex Medical Group plc


Trading update


16 December 2004: Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the AIM listed haemodynamic monitoring company, today announces an update on
expected trading performance in advance of the preliminary announcement of its
results for the year ending 31 December 2004.

The Company has made considerable progress in raising awareness of the clinical
and economic benefits of routine haemodynamic optimisation using its CardioQ(TM)
system. This progress has accelerated since 24 September 2004 when the Company
announced both the results of a new clinical study in Worthing and the results
of a post-procurement audit of wide-scale use of the CardioQ at the Medway
Maritime Hospital ('Medway'). Together with the significant body of clinical
evidence, these new results meant the Company could now demonstrate clearly to
both doctors and hospital administrators that using the CardioQ as a standard of
care delivers more cost effective, better quality of care for large numbers of
patients.

Our discussions in hospitals indicate that iincreasing numbers of anaesthetists,
surgeons and senior hospital managers have now recognised the importance of
implementing this change in the management of higher risk surgical patients. The
Company is currently working to conclude sales negotiations with 14 hospitals in
the UK National Health Service ('NHS') who are planning to implement routine,
wide-scale use of the Company's products. The Company has already reached
agreement in principle with a further six NHS hospitals which they will work
with the Company towards wide-scale purchase of the Company's product(s),
subject to focused local evaluations scheduled to be undertaken in the first
quarter of 2005. In addition clinicians at over 20 more NHS hospitals support
the adoption of CardioQ as a standard of care into priority uses of hospital
budgets in the NHS financial year beginning 1 April 2005.

In the USA, Deltex Medical has been working in partnership with the Veteran's
Administration (VA) Hospital in San Antonio to undertake a similar audit to that
concluded earlier in the year at Medway. The doctors at this site have
demonstrated to their own satisfaction that routine haemodynamic optimisation
delivers the clinical benefits and length of stay improvements in the setting of
the VA system and have already begun to modify treatment protocols based on
their experience. From 1 November 2004 haemodynamic optimisation was adopted as
a standard of care at the VA Hospital in San Antonio and requisitions have been
raised internally by the hospital to fund the increased numbers of monitors and
probes required to enable full implementation. These requisitions are supported
by the hospital's senior administrators.

The Company is also working with its distributor partners in Europe to establish
'flagship' hospital-wide adoption sites in five countries. These sites are
aiming to demonstrate over the first half of 2005 that the clinical, economic
and efficiency benefits demonstrated through the Medway post-procurement audit
can be achieved in their individual healthcare environments.

In order for the Company to report sales for the year ending 31 December 2004 in
line with current market expectations, it would be necessary for the majority of
the fifteen identified hospitals in the UK and USA to complete their internal
procurement processes and place an order with the Company in time for delivery
before 31 December. The Directors now consider it likely that several or
possibly even all of these hospitals will be unable to meet the timeframes which
the Company has proposed and that the Company's sales for the year will be lower
than market expectations by corresponding amounts. However, the Directors
remain confident that these orders will be forthcoming in the first half of
2005. The Directors continue to believe that the Company is well positioned to
make haemodynamic optimisation using its products a standard of care in a number
of major markets.




For further information, please contact:-

Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman
nigel.keen@deltexmedical.com


regards,

wilbs

Below are two more RNS announcements made recently.

Deltex Medical Group PLC 20 December 2004 Deltex Medical Group plc Additional Listing Deltex Medical Group plc (the 'Company') has been notified today that certain of its European distributors have acquired 500,000 ordinary shares of 1p each at a price of 211/4 pence per share as the result of the exercise of an option over 500,000 shares granted on 31 December 2003. Accordingly, application has been made for these shares to be admitted to trading on AIM. The shares rank pari passu with the existing issued shares of the Company and dealings are expected to commence on 23 December 2004. For a period of eighteen months following admission of these new ordinary shares, the European distributor has undertaken not to sell or dispose of any of these Ordinary Shares without the express written permission of the Company and that, in the event that it does sell or dispose of any of these shares in this time period, it will do so through the Company's broker from time to time (subject to certain limited exceptions). Following this additional listing, the number of shares in issue will be 69,083,253.
-----------------------------------------------------------------------------

Deltex Medical Group PLC 08 December 2004 Deltex Medical Group plc Appointment of German distributor for CardioQ(TM) 8 December 2004: Deltex Medical Group plc ('Deltex Medical'), the haemodynamic monitoring company, announces the appointment of P. J. Dahlhausen & Co. GmbH (Dahlhausen) as its distributor partner for CardioQ in Germany with immediate effect. Dahlhausen, based in Cologne, has manufactured and distributed medical devices throughout Germany for 150 years and has a strong reputation with hospitals across the country. They have a substantial field sales and clinical support force of 25 people covering all German hospitals. Germany's healthcare system is emerging from a period of significant reorganisation following the implementation of new funding and reimbursement systems aimed at addressing systemic cost and efficiency issues. Prior to entering into this arrangement, Dahlhausen's senior management asked their sales and marketing team to undertake a detailed evaluation of the potential for haemodynamic optimisation in Germany. This evaluation concluded that the proven economic and clinical benefits derived from the use of Deltex Medical's CardioQ monitor fit well with the new German healthcare regime. Dahlhausen also believes that the novel sales approaches developed by Deltex Medical for the UK market can effectively be tailored to fit the specific characteristics of the German market place. Chief Executive, Andy Hill commented: 'Germany is the final European territory in our strategic sales and distribution roll-out of CardioQ. While Germany represents the biggest medical technology market in Europe, it is also one of the more complex environments to do business in. Dahlhausen have demonstrated that they clearly understand the difficulties of their market and have the resources, human and intellectual, to create a successful platform from which to launch our products. I believe that our collaboration with Dahlhausen will help German doctors and healthcare managers to deliver to patients undergoing moderate and major surgery the highest quality care in the most cost effective manner.' Peter Dahlhausen, Managing Director of P. J. Dahlhausen & Co. GmbH commented: 'I am delighted that Dahlhausen will be working with Deltex Medical and look forward to developing a successful long-term relationship with the company. Feedback about the CardioQ from the sales and marketing team and our customers has been consistently positive and I believe we have a real opportunity to establish haemodynamic optimisation, using the CardioQ, as a standard of care for moderate and major surgery in Germany. Our initial focus will be on establishing wide-scale use of the CardioQ in selected key hospitals.'


Happy reading

wilbs

Strong buys this morning, i`m suprised the price hasn`t ticked up based on this strong demand. Would like to see a move up by the end of the day. D

Good strong buys. 118,222 buys compared to 7,500 sells. Lets hope we see a rise but imho I thing it may be quiet till 2005 when we will start to see some orders come in.

wilbs

wilbs - Thanks for excellent posts - wonder how these RNS slipped past MoneyAM or did I have my eyes shut - If not a Merry Christmas I do think we are in for a Very Happy New Year